Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.76 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.76 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.76 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.76 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.76 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.76 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.76 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.76 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.46 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.46 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.46 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.46 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.41 |
| ▸ | CACNA2D1 known ✓ | P54289 | 3/20 | 0.40 |
| ▸ | CACNA1B known ✓ | Q00975 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3377943 | 1.00 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL7479212 | 0.99 | ABCB11 (0.74) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Bromide SCHEMBL1402201 | 0.99 | ABCB11 (0.74) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL3173500 | 0.99 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL364610 | 0.99 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL19148650 | 0.99 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL30277249 | 0.99 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL233523 | 0.99 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL4770 | 0.99 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL13403893 | 0.99 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907397-B1 | METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO LTD (KR) | 2011-06-29 | — | — | EP | disclosed |
| US-7763730-B2 | Method preparation clopidogrel and intermediates used therein | HANMI PHARM. CO., LTD (KR) | 2010-07-27 | — | — | US | disclosed |
| US-7652140-B2 | Method of preparing clopidogrel and intermediates used therein | HANMI PHARM. CO., LTD (KR) | 2010-01-26 | — | — | US | disclosed |
| US-20090318701-A1 | METHOD PREPARATION CLOPIDOGREL AND INTERMEDIATES USED THEREIN | HANMI PHARM CO., LTD. (KR) | 2009-12-24 | — | — | US | disclosed |
| EP-1907397-A4 | METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN | HANMI PHARM IND CO LTD (KR) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214821-A1 | Method of Preparing Clopidogrel and Intermediates Used Therein | HANMI PHARM., CO., LTD. (KR) | 2008-09-04 | — | — | US | disclosed |
| EP-1907397-A1 | METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2008-04-09 | — | — | EP | disclosed |
| WO-2006137628-A1 | METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2006-12-28 | — | — | WO | disclosed |
| US-4529596-A | Anticoagulant; clopidogrel (Methyl Alpha -(4,5,6,7-tetrahydro-thieno(3,2-c)-5-pyridyl)-o-chlorophenyl-acetate) | SANOFI, S.A. (FR) | 1985-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318701-A1 | METHOD PREPARATION CLOPIDOGREL AND INTERMEDIATES USED THEREIN | P2RY11, PTGIS, P2RY13 | OPRM1 620/4885ADRA2A 324/4885OPRK1 1029/4885 |
| US-20080214821-A1 | Method of Preparing Clopidogrel and Intermediates Used Therein | P2RY11, PTGIS, PTGIR | OPRM1 632/4885ADRA2A 373/4885OPRK1 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.